High-profile presentations from the likes of Intercept and Alnylam remain under wraps before Europe’s biggest liver disease conference next month, but the early abstract…
Sanofi might only get the US go-ahead for its dengue vaccine Dengvaxia in a narrow population, leaving the door open for its rival Takeda.
Five months after Allogene’s flotation there are few signs of waning interest in new issues of cell therapy companies, and they all have one thing in common.
Others hoping to get FDA approvals include Sage Therapeutics and Novartis, but hopes look dimmer for Lexicon and Sanofi.
Funds backed by drugmakers remain visible contributors to the venture world, but several of the big corporate names seem to have reined in spending.
Climbing consensus sales forecasts for 2022 suggest that last year equity analysts brushed off concerns about pricing restraints.
Johnson & Johnson's esketamine should get approved in depression, but a safety plan requiring supervision raises questions about its commercial promise.
An upcoming Icer report will put the spotlight on unjustified price increases even as signs of moderation emerge.
Takeda gave biopharma’s M&A bill a big boost in 2018 but to see just how slow the year was, take a look at deal volumes.